Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

Inclusion Criteria:

• Healthy, adult, male or non-pregnant, non-lactating females

• Given written informed consent

• No clinically significant health problems

• Negative test for SARS-CoV-2

• Agree to avoid conception through Day 57

• Agree to minimize blood and body fluid exposures to others after vaccination throughDay 57

• Agree to avoid exposure to immunocompromised persons after vaccination through Day 57

• Agree to avoid employment in industry involved with livestock after vaccinationthrough Day 57

Exclusion Criteria:

• Prior infection with Nipah virus, related Henipaviruses or Ebola virus

• Prior infection with vesicular stomatitis virus (VSV)

• Received VSV-vectored vaccine or Ebola vaccine

• BMI < 18.5 or ≥ 35

• Healthcare worker with direct physical contact with patients

• Childcare worker in direct contact with children 5 years old or younger

• Household contact who is immunodeficient, or on immunosuppressive medication

• Hands-on food preparation job

• Primary care or treatment of cattle, horses, or swine

• Hepatitis B, hepatitis C, HIV-1, HIV-2, diabetes, atopic dermatitis (eczema),chronic inflammatory disease, autoimmune or autoinflammatory disorder, malignancy,chronic or active neurologic disorder

• History of severe reactions to any vaccine or history of severe allergies

• Receipt of investigational product up to 30 days prior to, or planned receipt within 196 days after randomization, or ongoing participation in another interventionalclinical trial.

• Receipt of licensed non-live vaccines within 14 days of planned study immunization (30 days for live vaccines) or planned receipt of non-live or live vaccine within 60days after first study immunization (30 days after the 2nd vaccination).

• Known allergy to components of PHV02

• Injection sites obscured by tattoos or physical condition

• Significant psychiatric or medical condition or laboratory abnormality on screening

• History of Guillain Barre Syndrome or any chronic or acute neurological disorder

• Alcohol or illicit drug abuse within past 5 years

• Pregnant or lactating female

• Administration of blood or IgG within 120 days preceding study

• History of blood donation within 60 days of study

• Unwilling to undergo diagnostic evaluation of rash (skin biopsy, if indicated) orjoint symptoms (arthrocentesis if indicated by joint effusion), in both cases ifacceptable to subject

• Elective surgery planned during the study period